The drug, ANX-201, combined at fixed ratios with nucleoside and nucleotide reverse transcriptase inhibitors (N(t)RTIs) including zidovudine, tenofovir, abacavir, lamivudine, emtricitabine and stavudine resulted in synergistic to additive
A decision by the FDA on the label revision is expected by the end of March 2008. “We are pleased to report the FDA acceptance of this filing
The open offer for Matrix could be a first step in delisting the company from the stock markets, which would release the company from its regulatory obligations, the
The study will be conducted within a network of approximately 25 sites under the direction of the National Cancer Institute funded Community Clinical Oncology Program, according to the
Metabolex will receive a milestone payment from Ortho-McNeil, which holds an exclusive license for worldwide development and commercialization of MBX-102/JNJ 39659100. The company expects to share results from
The transaction provides Amgen with a late-stage phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on hemodialysis. The deal was originally announced June 4.
In a press release, MedImmune said that the trial is the third clinical study of the antibody currently underway. MEDI-545 is also being evaluated in a single-dose Phase
TAK-491 is an angiotensin receptor blocker (ARB) discovered by Takeda that lowers blood pressure. Takeda said that TAK-491 is expected to show stronger anti-hypertensive action, and also to
Additional preliminary results from preclinical tests in small animals on Viprovex in conjunction with Tamiflu (Roche’s FDA-approved influenza prophylactic and treatment) show that treating subjects with both Viprovex
The product candidate underlying the agreement is being developed to treat a significant CNS disorder and is based on Antares’ proprietary ATD (Advanced Transdermal Delivery) drug delivery platform,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.